AMAG Pharmaceuticals (AMAG) Announces Quarterly Results
AMAG Pharmaceuticals (NASDAQ:AMAG) issued its quarterly earnings data on Thursday. The company reported ($0.17) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.10) by $0.07, AmericanBankingNews.com reports. The company had revenue of $21.70 million for the quarter, compared to the consensus estimate of $21.01 million.
A number of analysts have recently weighed in on AMAG shares. Analysts at Summer Street cut their price target on shares of AMAG Pharmaceuticals to $30.00 in a research note to investors on Thursday, January 23rd. They now have a “buy” rating on the stock. On the ratings front, analysts at Jefferies Group upgraded shares of AMAG Pharmaceuticals from an “underperform” rating to a “hold” rating in a research note to investors on Thursday, January 23rd. They now have a $19.00 price target on the stock, up previously from $16.00. Finally, analysts at Ladenburg Thalmann downgraded shares of AMAG Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note to investors on Wednesday, January 22nd. They noted that the move was a valuation call. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $24.40.
Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) opened at 20.36 on Thursday. AMAG Pharmaceuticals has a one year low of $15.90 and a one year high of $28.42. The stock has a 50-day moving average of $22.39 and a 200-day moving average of $23.35. The company’s market cap is $442.5 million.
AMAG Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (NASDAQ:AMAG).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.